Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Rehan Kahloon

Interventional Cardiology Chattanooga, TN Medical Doctor

NPI 1497015150 CMS profile 5701479

979 E 3Rd St Ste C-520, Chattanooga, TN 37403

Open in the dashboard

General payments

$8,895

283 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$3,825 paid to institutions, not to them · program years 2020–2021

Through program year 2025, Rehan Kahloon of Chattanooga, TN is reported in the CMS Open Payments database as having received $8,895 across 283 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $3,825 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 55th percentile of Interventional Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,495 59
2024 General $1,217 44
2023 General $1,332 56
2022 General $1,229 40
2021 General $1,159 39
2020 General $561 26
2019 General $902 19

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Rehan Kahloon
  • Interventional Cardiology median
  • Middle half of Interventional Cardiology
  • National median

In program year 2025, general payments to Rehan Kahloon were reported at $2,495. Among 6,173 Interventional Cardiology profiles paid that year, the median was $1,092 and the middle half received between $366 and $3,019.

Show as a table
Year Rehan Kahloon Interventional Cardiology median Middle half National median
2019 $902 $1,097 $329–$3,048 $163
2020 $561 $473 $161–$1,480 $114
2021 $1,159 $677 $233–$1,827 $132
2022 $1,229 $978 $333–$2,724 $149
2023 $1,332 $1,136 $382–$2,986 $160
2024 $1,217 $1,181 $395–$3,326 $164
2025 $2,495 $1,092 $366–$3,019 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Abbott Laboratories $1,698 56 payments
  2. HeartFlow, Inc. $1,413 5 payments
  3. Boston Scientific Corporation $1,034 18 payments
  4. Novartis Pharmaceuticals Corporation $936 55 payments
  5. Medtronic, Inc. $716 20 payments
  6. Janssen Pharmaceuticals, Inc $392 22 payments
  7. E.R. Squibb & Sons, L.L.C. $324 15 payments
  8. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $308 14 payments
  9. CVRx, Inc. $278 5 payments
  10. Abiomed $276 3 payments
  11. Other $1,518 70 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $7,199 276 payments
  2. Travel and Lodging $1,122 3 payments
  3. Grant $563 3 payments
  4. Education $11 1 payment
Products named General payments · program years 2019–2025
  1. FFRct $1,413 5 payments
  2. CARDIOMEMS $677 25 payments
  3. CardioMEMS HF System $597 11 payments
  4. GENERAL ATHERECTOMY $536 1 payment
  5. LEQVIO $529 33 payments
  6. XARELTO $392 22 payments
  7. LifeVest $308 14 payments
  8. AURORA EV-ICD MRI SURESCAN $306 5 payments
  9. Barostim Neo System $278 5 payments
  10. ENTRESTO $252 14 payments
  11. Other $3,909 159 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 34 drugs

Part D claims

1,988

Median for Interventional Cardiology: 2,236

Drug cost

$384,211

Median for Interventional Cardiology: $380,412

Branded share of claims

32.1%

Median for Interventional Cardiology: 27.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 111 $106,014
Entresto Sacubitril/Valsartan Brand 91 $86,974
Xarelto Rivaroxaban Brand 48 $61,563
Farxiga Dapagliflozin Propanediol Brand 40 $42,159
Brilinta Ticagrelor Brand 41 $31,713
Repatha Sureclick Evolocumab Brand 27 $25,871
Jardiance Empagliflozin Brand 17 $12,859
Rosuvastatin Calcium Generic 179 $1,880
Bumetanide Generic 35 $1,499
Ranolazine Er Ranolazine Brand 24 $1,332

The 10 drugs with the highest cost, of 34 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 4,694 Part D prescribers listed as Interventional Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 39 billing codes

Paid by Medicare

$74,682

Medicare's payments for the services billed

Medicare patients

427

Average age 75

Services billed

1,066

187 women, 240 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 58%
Arthritis 58%
Diabetes 46%
Heart failure 46%
Atrial fibrillation 44%
Chronic kidney disease 39%
COPD 30%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 7 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VYNDAQEL
  • PFIZER INC. $86
$86 — —
LEQVIO
  • Novartis Pharmaceuticals Corporation $71
$71 — —
Repatha
  • Amgen Inc. $65
$65 27 —
ZEPOSIA
  • Celgene Corporation $30
$30 — —
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $20
$20 17 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 7 in the dashboard with a free account

Records

283 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Cardiology in Tennessee

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record